MedTrace Logo

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

NCT06804096 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-07-11

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.

Conditions

  • Pneumonia, Community-Acquired
  • Bacterial Pneumonia

Interventions

DRUG

Faropenem

Tab. Faropenem 200mg three times daily

DRUG

Co-amoxiclav

Tab. Co-Amoxiclav 625mg three times daily

DRUG

Clarithromycin 500 mg

Tab. Clarithromycin 500mg two times daily

Sponsors & Collaborators

  • Dr. Md. Alimur Reza

    lead INDUSTRY

Principal Investigators

  • Prof. Khan Abul Kalam Azad · Popular Medical College Hospital

  • Prof. Quazi Tarikul Islam, MBBS, FCPS, FACP (USA), FRCP, · Popular Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-20
Primary Completion
2025-09-30
Completion
2025-12-01

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06804096 on ClinicalTrials.gov